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Abstract 
This is an update to the 2014 Canadian Hereditary Angioedema Guideline with an expanded scope to include the 
management of hereditary angioedema (HAE) patients worldwide. It is a collaboration of Canadian and international 
HAE experts and patient groups led by the Canadian Hereditary Angioedema Network. The objective of this guideline 
is to provide evidence‑based recommendations, using the GRADE system, for the management of patients with 
HAE. This includes the treatment of attacks, short‑term prophylaxis, long‑term prophylaxis, and recommendations 
for self‑administration, individualized therapy, quality of life, and comprehensive care. New to the 2019 version of 
this guideline are sections covering the diagnosis and recommended therapies for acute treatment in HAE patients 
with normal C1‑INH, as well as sections on pregnant and paediatric patients, patient associations and an HAE registry. 
Hereditary angioedema results in random and often unpredictable attacks of painful swelling typically affecting 
the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional 
impairment, decreased health‑related quality of life, and mortality in the case of laryngeal attacks. Caring for patients 
with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada, as in 
many countries, continues to be neither optimal nor uniform. It lags behind some other countries where there are 
more organized models for HAE management, and greater availability of additional licensed therapeutic options. It is 
anticipated that providing this guideline to caregivers, policy makers, patients, and advocates will not only optimize 
the management of HAE, but also promote the importance of individualized care. The primary target users of this 
guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use 
this guideline are emergency and intensive care physicians, primary care physicians, gastroenterologists, dentists, 
otolaryngologists, paediatricians, and gynaecologists who will encounter patients with HAE and need to be aware of 
this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.
Keywords: Hereditary angioedema, Guideline, Recommendations, Pediatrics, Pregnancy, Acute attacks, Short‑term 
prophylaxis, Long‑term prophylaxis, Quality of life, Patient registry
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Allergy, Asthma & Clinical Immunology
*Correspondence:  betschels@smh.ca
1 University of Toronto, Toronto, ON, Canada
Full list of author information is available at the end of the article
Page 2 of 29Betschel et al. Allergy Asthma Clin Immunol           (2019) 15:72 
Background
Hereditary angioedema (HAE) results in random and 
often unpredictable attacks of painful swelling typically 
affecting the extremities, bowel mucosa, genitals, face 
and upper airway [1]. Attacks are associated with 
significant functional impairment, decreased health-
related quality of life (HRQoL), and mortality in the case 
of laryngeal attacks [2, 3].
HAE can be categorized into 3 different types including 
HAE with deficit C1-inhibitor levels (HAE-1), HAE with 
dysfunctional C1-inhibitor (HAE-2), and HAE with 
normal C1-inhibitor function (HAE nC1-INH) previously 
referred to as type 3 (Table  1). HAE-1 and HAE-2 
are autosomal dominant conditions with a combined 
estimated prevalence of approximately 1:50,000, although 
25% of patients may have no family history [4, 5]. HAE-1 
is the most prevalent, representing approximately 85% 
of cases, and results from low antigenic and functional 
levels of C1-INH. HAE-2 accounts for approximately 
15% of cases and is associated with a normal C1-INH 
protein concentration but impaired C1-INH function 
[6, 7]. C4 is reduced in 98% of cases for both HAE-1 and 
HAE-2, and nearly 100% of the time during an attack 
[6]. The swelling in HAE-1/2 is a result of impaired 
regulation of bradykinin synthesis [8]. Bradykinin is a 
nonapeptide kinin formed from high molecular weight 
kininogen by the action of plasma kallikrein. Bradykinin 
is a very powerful vasodilator that increases capillary 
permeability, constricts smooth muscle, and stimulates 
pain receptors [4, 5].
HAE nC1-INH is much less prevalent than HAE-1 
and HAE-2, and the true prevalence is not known. 
Identifying patients with HAE nC1-INH is more difficult 
than identifying those with HAE-1/2 due to the lack of 
accessible and available assays, including genetic testing 
for diagnosis. While HAE nC1-INH presents similarly, 
its pathogenesis has not been clearly defined. Its causes 
can be subdivided into four groups: HAE-FXII, HAE-
ANGPT1, HAE-PLG, and HAE-UNK. Four distinct 
variants in the gene coding for coagulation factor XII 
(FXII) can lead to HAE-FXII. One of these variants, 
Thr328Lys, is far more common. These variants create a 
cleavage site for plasmin, which facilitates the activation 
of FXII and the generation of bradykinin. Several aspects 
of the pathogenesis and the penetrance of HAE-FXII 
remain unclear including the role of estrogens [12]. 
In HAE-ANGPT1, a variant in the angiopoietin-1 
gene (ANGPT1) impairs its ability to limit vascular 
permeability. In HAE-PLG, the plasminogen gene (PLG) 
is affected, but the mechanism of action is unknown. 
HAE-FXII accounts for about one third of HAE nC1-INH 
cases [13–15] while the majority are HAE-UNK. The 
term HAE-UNK refers to HAE nC1-INH where both the 
cause and pathogenesis remain unknown [11]. A previous 
international consensus group published criteria to make 
the diagnosis of HAE nC1-INH [16]. These included: 
(1) a history of recurrent angioedema in the absence of 
concomitant hives or use of medication known to cause 
angioedema; (2) documented normal or near normal C4, 
C1-INH antigen, and C1-INH function; and (3) either a 
genetic variant associated with the disease, or a family 
history of angioedema and documented lack of efficacy 
of chronic high-dose antihistamine therapy.
Management of HAE can be divided into various 
approaches. The aim of acute treatment of HAE attacks, 
also referred to as “on-demand therapy”, is to minimize 
their severity and duration, including potentially fatal 
upper airway edema and associated impairment of 
quality of life (QoL). Short-term prophylaxis (STP) refers 
to treatment meant to minimize the risk of attacks when 
exposure to a potential or known trigger is anticipated. 
Long-term prophylaxis (LTP) refers to ongoing treatment 
of HAE aimed at minimizing the overall number, 
frequency and/or severity of attacks. The details of 
specific therapies for these treatment approaches will 
be discussed in the sections that follow. In addition to 
the evidence behind the proposed recommendations, 
the “Clinical Considerations” section following each 
recommendation provides a practical clinical context to 
assist clinicians in managing individual patients.
Scope and purpose
The objective of this guideline is to provide evidence-
based recommendations for the management of patients 
in Canada and internationally with HAE-1, HAE-2, and 
HAE nC1-INH. This includes the treatment of attacks, 
STP, LTP, and recommendations for self-administration, 
individualized therapy, QoL and comprehensive care. 
New to the 2019 international/Canadian version of 
this guideline are sections covering the diagnosis and 
recommended therapies for acute treatment in patients 
with HAE nC1-INH, as well as sections on pregnant and 
paediatric HAE patients, patient associations and an 
HAE registry.
Table 1 Laboratory findings in  hereditary angioedema 
[9–11]
Function C4 C1-INH antigen C1-INH
HAE‑1 ↓ ↓ ↓
HAE‑2 ↓ normal or ↑ ↓
HAE‑nC1INH variants
 coagulation factor XII
 angiopoietin‑1
 plasminogen
 unknown
normal normal normal
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The care of patients with HAE in Canada, as in many 
countries, is neither optimal nor uniform. It lags behind 
some other countries where there are more organized 
models for HAE management and greater availability 
of additional licensed therapeutic options [17, 18]. 
It is anticipated that providing this international/
Canadian guideline to caregivers, policy makers, patients, 
and advocates will not only optimize the management of 
HAE, but also promote the importance of individualized 
care.
Intended audience
The primary target users of this guideline are healthcare 
providers who are managing patients with HAE-1, HAE-
2, and HAE nC1-INH. Other healthcare providers who 
may use this guideline are emergency and intensive care 
physicians, primary care physicians, gastroenterologists, 
dentists, otolaryngologists, paediatricians, and 
gynaecologists who will encounter patients with 
HAE and need to be aware of this condition. Hospital 
administrators, insurers, and policy makers may also find 
this guideline helpful.
Methods
Committee Members, Guideline Authors and Conference 
Participants
The Canadian Hereditary Angioedema Guideline 
Committee (“the Committee”) is a working committee 
under the umbrella of the Canadian Hereditary Angioedema 
Network (CHAEN)/Réseau Canadien d’angioédème 
héréditaire (RCAH) http://chaen -rcah.ca/. Members of 
this committee included members from CHAEN/RCAH 
across Canada, as well as the President of the Canadian 
HAE Patient Organization, Hereditary Angioedema Canada 
(HAEC). The Committee was responsible for defining 
the scope and purpose of the guideline and choosing 
the international participants. International participants 
were selected based on their relevant expertise in HAE 
and its management, and guideline priorities including 
self-administration, individualized therapy, HRQoL, 
and comprehensive care, in addition to new sections on 
pregnant and paediatric HAE patients, and HAE nC1-
INH. There was also representation from Angio-oedème 
Héréditaire du Québec (AOHQ) and members of the global 
HAE patient group, HAE International (HAEi). Identified 
experts were asked to present a summary of the evidence 
related to these areas at the CHAEN/RCAH Guideline 
Conference (“the Conference”).
Guideline Authors represented healthcare providers 
who are the intended users of this guideline. They 
included the Committee, international experts, registered 
members of CHAEN, the President of HAEC and AOHQ 
Canada and their designates, and the Executive Director 
and the President of HAEi. Representatives from Héma-
Québec and Canadian Blood Services were invited as 
observers. An invitation was extended to representatives 
of the provincial/territorial blood coordinating offices, 
but was declined. All Guideline Authors were asked to 
submit standard ICMJE conflict of interest forms, which 
were vetted by an independent reviewer for potential 
conflicts. “Conference Participants” were the Guideline 
Authors who were able to attend the Conference. 
“We” refers to Guideline Authors who voted on the 
recommendations (see Recommendation Development 
and Approval below for further details).
Identifying the evidence
A librarian from the Centre for Effective Practice 
conducted a systematic search using Ovid MEDLINE on 
June 27, 2018, based on the predefined scope as described 
in Appendix 1. The search was designed to identify the 
current evidence on long- and short-term prophylaxis 
and acute treatment of attacks in patients of any age 
diagnosed with HAE-1, HAE-2, or HAE nC1-INH. The 
search was repeated on November 4, 2018 using the same 
search strategy to ensure that the most recent evidence 
was considered at the Conference held from November 
30 to December 2, 2018.
Outcomes of interest included frequency or severity 
of attacks, symptom relief, or quality of life measures 
as reported or measured by the subject or investigator. 
Studies were limited to English language publications 
that were published and indexed in MEDLINE since the 
search was conducted for the 2014 Canadian Hereditary 
Angioedema Guideline in October 2013 [19].
198 unique results were identified in the search, and 
two reviewers independently applied the predetermined 
inclusion criteria to the titles and abstracts. If either reviewer 
indicated that a result required further consideration at the 
title and abstract review stage, the full text document was 
retrieved and reviewed by both reviewers.
106 results were retrieved and reviewed in full text 
by both reviewers. Any disagreements between the 
reviewers were discussed electronically until consensus 
was reached. Ten relevant randomized controlled trials 
and 15 lower-quality studies met the inclusion criteria 
and were included in evidence tables. The complete 
search strategy and inclusion criteria are provided in 
Appendix 1.
All 416 results previously identified in the October 
2013 search were examined to determine if any met the 
inclusion criteria for the new populations of interest for 
this guideline (i.e., pregnant and paediatric populations). 
One result identified in the 2013 search met the inclusion 
criteria and was included in the evidence table for lower-
quality studies.
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To ensure the comprehensiveness of the evidence base, 
the Committee was invited to suggest additional papers 
for consideration. One study that was published after 
the November 2018 search, which met the inclusion 
criteria, was identified by the Committee and added to 
the evidence table for randomized controlled trials.
With the addition of these two results, 11 randomized 
controlled trials and 16 lower-quality studies without 
randomization or blinding met the inclusion criteria, and 
were entered into evidence tables.
Summarizing and evaluating the evidence
Key information from the included studies such as study 
design, number of patients, outcome measures, side 
effects and funding source was extracted into evidence 
tables for each intervention (see Additional files 1, 2). 
Evidence tables were provided to the Committee and 
were available for reference at the Conference.
Criteria for determining Levels of Evidence and 
Strength of Recommendation were adapted from the 
GRADE system [20–22], and the process was based 
primarily on the Journal of Clinical Epidemiology’s 
2011–2013 series of articles describing the GRADE 
methodology. The method applied here involved 
evaluating the quality of each study, and then evaluating 
the studies together to assign a Level of Evidence based 
on the collection of studies. Each identified randomized 
controlled trial was assessed by two reviewers for 
quality using the Cochrane Risk of Bias Tool [23]. A 
third reviewer resolved any disagreements. Randomized 
trials were initially rated as high-quality level of 
evidence, with quality being downgraded for evidence 
of bias on the Cochrane tool if there was evidence of 
inconsistency (Appendix 2: Table  5). Non-randomized, 
non-blinded trials were considered to be low-quality 
evidence.
Appendix 2 provides additional detail on how quality 
was assessed and the criteria used to determine the 
Strength of Recommendation. The quality ratings were 
presented at the Conference during the discussion of 
draft recommendations.
Recommendation development and approval
The Committee reviewed recommendations that 
were unlikely to change from the last guideline. The 
Chair then sent out these recommendations for pre-
approval by all voting Guideline Authors prior to the 
Conference. For all remaining topics, content experts 
were assigned specific topic areas and were asked to 
review the provided evidence tables relevant to their 
topic and present the body of evidence for consideration 
at the Conference. After the summary was presented, 
Conference Participants were provided an opportunity 
to discuss the literature. Following this discussion, the 
draft recommendation was presented and the group 
discussed the specific wording of the recommendation 
before voting anonymously via electronic voting to 
agree or disagree with the recommendation, or abstain. 
If 80% consensus was not reached, there was additional 
group discussion, the recommendation was rephrased, 
and a new vote conducted. This process was conducted 
a maximum of three times. If 80% consensus was not 
reached, it was determined that the group was unable to 
reach consensus.
Once Conference Participants approved the phrasing 
of a recommendation, the guideline methodologist 
presented the proposed Level of Evidence (High, 
Moderate, Low, Very Low, or Consensus). The Level of 
Evidence was then discussed, revised if necessary, and 
similarly voted on as outlined above.
The suggested Strength of Recommendation 
(Strong or Weak) was then presented to the group. 
The guideline methodologist proposed a Strength of 
Recommendation based on the Level of Evidence, the 
balance between desirable and undesirable effects, 
values, and preferences. These factors were discussed 
amongst the group before voting to accept the proposed 
Strength of Recommendation. All votes were recorded 
and presented in real time with the recommendations. 
Table  2 is a summary of all the recommendations, the 
level of evidence supporting each recommendation, and 
the strength of each recommendation.
For each topic area, group discussions were recorded 
and used to inform the clinical considerations for each 
recommendation.
Prior to the Conference, the Committee determined 
that open discussion amongst Conference Participants 
regarding an approach to individualized therapy would 
be beneficial. For this topic, small round table discussions 
were facilitated prior to recommendation review and 
voting, and additional clinical considerations were 
evaluated.
Guideline recommendations
Diagnosis of HAE-1/2
Background
The consequences of undiagnosed HAE can be severe. 
One study demonstrated a mortality rate of 31.4% for 
undiagnosed HAE patients (n = 63/201) compared to 
1.33% in diagnosed patients (n = 7/527) [1]. Without 
an accurate diagnosis, patients may be unable to access 
appropriate medications to prevent morbidity and 
mortality, and may be subject to stigmatization because 
of their condition. The diagnosis of HAE-1/2 should 
be based on a thorough history and clinical features 
supportive of the disease. HAE should be suspected 
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Table 2 Summary of recommendations
Recommendation Level of evidence and strength of recommendation
Diagnosis of HAE
1. The diagnosis of HAE‑1/2 should be made by measuring plasma levels of C4, C1‑INH 
antigen and, when necessary, C1‑INH function
High, Strong
2. All individuals with a positive family history should be considered to be at risk of HAE and 
should be screened as early as possible
Consensus, Strong
Acute treatment of HAE-1 and HAE-2
3. Effective therapy should be used for the acute treatment of attacks of angioedema to 
reduce duration and severity of attacks
High, Strong
4. Intravenous pdC1‑INH is an effective therapy for the acute treatment of attacks High, Strong
5. Icatibant is an effective therapy for the acute treatment of attacks High, Strong
6. Ecallantide is an effective therapy for the acute treatment of attacks High, Strong
7. Intravenous rhC1‑INH is an effective therapy for the acute treatment of attacks High, Strong
8. Attenuated androgens should not be used for the acute treatment of attacks Low, Strong
9. Tranexamic acid should not be used for the acute treatment of attacks Low, Strong
10. Frozen plasma could be used for acute treatment of attacks if other recommended 
therapies are not available
Low, Strong
11. Attacks should be treated early to reduce morbidity (level of evidence: moderate) and 
mortality (level of evidence: consensus)
Moderate, Strong/Consensus, Strong
12. All attacks of angioedema involving the upper airway are medical emergencies and must 
be treated immediately
Low, Strong
Acute treatment and short-term prophylaxis of HAE in pregnant patients
13. pdC1‑INH is the treatment of choice for angioedema attacks in pregnant HAE‑1/2 patients Consensus, Strong
Acute treatment of HAE in paediatric patients
14. All paediatric patients diagnosed with HAE should have access to acute treatment, 
including those that are symptom free
Consensus, Strong
15. Intravenous pdC1‑INH is an effective therapy for the acute treatment of HAE‑1/2 attacks in 
paediatric patients
Moderate, Strong
16. Icatibant is an effective therapy for the acute treatment of HAE‑1/2 attacks in paediatric 
patients
Consensus, Strong
17. Intravenous rhC1‑INH is an effective therapy for the acute treatment of HAE‑1/2 attacks in 
paediatric patients
Consensus, Strong
18. Ecallantide is an effective therapy for the acute treatment of HAE‑1/2 attacks in adolescent 
patients
Consensus, Strong
Diagnosis of HAE with normal C1-inhibitor
19. If the diagnosis of HAE nC1‑INH is suspected, a referral should be made to a physician who 
has expertise with this condition. Testing for gene variants known to be associated with the 
condition should be performed
Low, Strong
Acute treatment of HAE with normal C1-inhibitor
20. pdC1‑INH is an effective therapy for the acute treatment of attacks in patients with HAE 
nC1‑INH
Moderate, Strong
21. Icatibant is an effective therapy for the acute treatment of attacks in patients with HAE 
nC1‑INH
Consensus, Strong
Short-term prophylaxis
22. Short‑term prophylaxis should be considered prior to known patient‑specific triggers and 
for any medical, surgical or dental procedures
Low, Strong
23. HAE‑specific acute treatment should be available during and after any procedure Low, Strong
24. Intravenous pdC1‑INH should be used for short‑term prophylaxis in patients with HAE Consensus, Strong
Long-term prophylaxis in HAE-1 and HAE-2
25. Long‑term prophylaxis may be appropriate for some patients to reduce frequency, 
duration, and severity of attacks
High, Strong
26. pdC1‑INH is an effective therapy for long‑term prophylaxis in patients with HAE‑1/2 High, Strong
27. Lanadelumab is an effective therapy for long‑term prophylaxis in patients with HAE‑1/2 High, Strong
28. Subcutaneous C1‑INH or lanadelumab should be used as first‑line therapy for long‑term 
prophylaxis in patients with HAE‑1/2
Consensus, Strong
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in patients who have recurrent angioedema without 
concomitant urticaria and also in patients who have 
recurrent abdominal pain for which no cause is identified, 
particularly if there is a family history. Healthcare 
providers should keep in mind that medications known 
to cause angioedema, such as angiotensin-converting 
enzyme inhibitors (ACEi) and estrogen-containing oral 
contraceptives, do not automatically rule out a diagnosis 
of HAE since these are also associated with angioedema 
attacks in affected individuals.
In a patient suspected to have HAE-1/2, plasma C4 
level is a valuable screening test, with most of those 
affected having a reduced level between attacks [24] and 
nearly 100% having a low level during attacks [6, 7]. If C4 
is low, further tests can distinguish HAE-1, which has 
low antigenic C1-INH levels and low functional C1-INH 
levels, from HAE-2, which has normal antigenic C1-INH 
levels but low functional C1-INH levels. Results should 
be confirmed with duplicate laboratory investigations 
after initial testing. However, HAE-specific treatment 
should not be delayed while awaiting confirmatory 
testing.
The Committee affirmed that the diagnosis and 
management of acquired C1-INH deficiency is not a 
specific focus of this guideline.
Clinical considerations
The availability of assays used to diagnose HAE can 
vary considerably around the world. Although assays 
Table 2 (continued)
Recommendation Level of evidence and strength of recommendation
29. Attenuated androgens and anti‑fibrinolytics should not be used as first‑line therapy for 
long‑term prophylaxis in patients with HAE‑1/2
Consensus, Strong
30. Attenuated androgens are an effective therapy for long‑term prophylaxis in some patients 
with HAE‑1/2
Moderate, Strong
31. All patients should have a management plan including immediate access to effective 
treatment for attacks, even when on prophylaxis
Consensus, Strong
Long-term prophylaxis in pregnant HAE patients
32. When long‑term prophylaxis is indicated in pregnancy, pdC1‑INH is the treatment of 
choice
Consensus, Strong
33. Attenuated androgens should not be used during pregnancy or during the breastfeeding 
period
Consensus, Strong
Long-term prophylaxis in paediatric HAE patients
34. When long‑term prophylaxis is indicated in paediatric patients, pdC1‑INH is the treatment 
of choice
Consensus, Strong
35. Androgens should not be used for long‑term prophylaxis in paediatric patients Moderate, Strong
Self-administration
36. All HAE patients should be trained on self‑administration of HAE‑specific therapies if they 
are suitable candidates. If patients cannot self‑administer therapy, provisions should be 
made to ensure timely access to all appropriate therapies
Low, Strong
Approach to individualized therapy
37. The decision to start or stop long‑term prophylaxis depends on multiple factors and 
should be made by the patient and an HAE specialist
Consensus, Strong
Quality of life
38. Healthcare providers should routinely assess quality of life in HAE patients using validated 
instruments in order to optimize HAE management
Consensus, Strong
Comprehensive care
39. Comprehensive care for all patients with HAE should be provided to optimize treatment 
and outcomes
Consensus, Strong
40. All HAE patients should be informed about HAE patient association(s) Consensus, Strong
Registries
41. Physicians should participate in an HAE registry and offer patients enrolment Consensus, Strong
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to measure C4 are widely available and relatively 
inexpensive, C4 level alone should not be used to confirm 
or rule out a diagnosis of HAE-1/2 [7].
When diagnosing HAE-1/2 in pregnancy, serum 
C1-INH testing should be interpreted with care as levels 
of C1-INH can be temporarily low but normalize after 
delivery in normal pregnancy [25]. The test should be 
repeated postpartum for confirmation.
Diagnosis in infants can also pose a problem. The 
C1-INH concentration in umbilical cord blood of healthy 
neonates is usually lower than that of the normal adult 
value [26]. Interpretation of C1-INH levels and function 
can lead to an inaccurate diagnosis in infants less than 
12  months old. As such, C1-INH test results should be 
confirmed after 1 year of age [27]. Given the diagnostic 
uncertainty of biochemical tests in young children, 
genetic testing might be a useful option for determining 
whether a child has inherited HAE-1/2 provided the 
variant in the affected parent is known.
Clinical considerations
HAE is an autosomal dominant disease, which gives 
every offspring of an individual with HAE a 50% chance 
of inheriting the disease. However, a negative family 
history does not rule out the possibility that a patient has 
HAE. Up to 25% of cases are caused by de novo genetic 
variants [4, 28], meaning that many patients may be 
affected without a family history of HAE.
Acute treatment of HAE-1 and HAE-2
Background
Attacks of HAE may be spontaneous or precipitated by 
external stimuli and range from mild to life threatening. 
The decision to treat an attack depends on many variables 
and the severity of an attack cannot always be predicted 
by its earliest manifestations. The aim of treating an 
attack is to reduce the duration and severity of an attack, 
to minimize the impact of an attack on the functional 
ability of the patient, and reduce morbidity and potential 
mortality.
Despite the increase in available efficacious therapies, 
some therapies, which have not been demonstrated to be 
effective in trials, continue to be used to treat attacks due 
to either historical precedent or lack of awareness.
Ten randomized trials were identified which 
demonstrated improvement in duration and severity of 
attacks of HAE-1/2 [29–38]. The therapies studied were 
plasma-derived C1-INH (pdC1-INH), recombinant human 
C1-INH (rhC1-INH), icatibant and ecallantide. Table  3 
lists the specific agents, their mechanism of action, their 
licensed indications internationally, the recommended 
dosages, and important potential adverse reactions. The 
quality of the evidence for the studies is described under 
the drug-specific recommendations that follow. We 
determined this body of evidence to be of high quality, 
based on the rating of each study using the Cochrane Risk 
of Bias Tool (see Additional file 1) and the overall consistent 
effect of therapy on the relevant outcomes (reduction of 
duration and severity of attacks and effect size).
Based on the Level of Evidence, the potential severity 
of the outcomes and the low risk of adverse events, we 
voted for a strong recommendation in favour of the use 
of effective therapies for the acute treatment of attacks. 
Clinical considerations
We emphasized the importance of healthcare 
professionals only using effective therapies supported 
by evidence, specifically not using non evidence-
based therapies such as antihistamines, corticosteroids 
and epinephrine, which treat histamine-mediated 
angioedema. In addition to acute therapy, patients 
should discontinue and avoid any known triggers such as 
estrogen-containing oral contraceptives or replacement 
therapy, dipeptidyl peptidase IV (DPP-IV) inhibitors, 
neprilysin inhibitors, and ACE inhibitors [39–46].
Clinical considerations
Plasma-derived (pd) C1-INH is a human blood product. 
Treatment with pdC1-INH replaces the deficient protein 
in patients with HAE-1/2. It has been shown to effectively 
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treat attacks of HAE-1/2 in adults and children [31], and 
is administered either by healthcare professionals or by 
patients and their caregivers who have been trained in its 
administration.
The recommended dose for acute treatment of 
attacks is derived from clinical trials. There have been 
no head to head trials comparing products so it cannot 
be concluded that they all have equivalent efficacy. The 
pdC1-INH products are safe and well tolerated when 
used as indicated, with no documented transmission of 
infectious agents.
Clinical considerations
Bradykinin is a key mediator in inducing angioedema 
through activation of the bradykinin B2 receptor 
[8]. Icatibant is a synthetic decapeptide and acts as a 
selective bradykinin B2 receptor competitive antagonist. 
It is administered as a single 30  mg subcutaneous (SC) 
injection. It is generally systemically well tolerated, 
although 97% of patients experience transient local pain, 
swelling, and erythema at the injection site.
Clinical considerations
Plasma kallikrein generates bradykinin through 
cleavage of high-molecular-weight kininogen [8, 47, 
48]. Ecallantide is a 60-amino acid recombinant protein 
that selectively and reversibly inhibits kallikrein. It is 
administered as three 10  mg SC injections for a total 
dose of 30  mg [49]. It has been shown to effectively 
treat attacks in adolescent and adult patients with 
HAE-1/2 [35]. Hypersensitivity reactions have been 
described with this agent in 5% of administrations, of 
which approximately 50% were possible anaphylactic 
reactions. It should only be administered by a healthcare 
practitioner in a location where anaphylaxis can be 
appropriately managed. 
Clinical considerations
Recombinant human (rh) C1-INH (conestat-α) is 
generated in the mammary glands of transgenic rabbits, 
and is identical to pdC1-INH except for the degree of 
protein glycosylation [50]. This difference in glycosylation 
results in shorter plasma mean half-life of the recombinant 
product [51, 52], however the effect this has on physiologic 
activity is not known [53]. It has been shown to effectively 
treat attacks in children 13  years of age and older 
and adults with HAE-1/2 [37]. Because of an isolated 
anaphylactic reaction after administration of rhC1-INH 
to a rabbit-allergic person, those known or suspected of 
having a rabbit allergy should not receive rhC1-INH.
 
Clinical considerations
Attenuated androgens such as the 17 α-alkylated anabolic 
androgen danazol and anti-fibrinolytic drugs such as 
tranexamic acid have not been shown to be efficacious 
in the acute treatment of attacks of HAE-1/2. Given the 
lack of evidence for these agents in the acute treatment of 
HAE, we strongly agreed that they should not be used for 
the treatment of acute HAE attacks.
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Clinical considerations
Frozen plasma (FP) is a blood product, which contains 
C1-INH in association with other plasma proteins. FP is 
not as safe as solvent detergent plasma (SDP) with respect 
to pathogen inactivation, and the level of evidence that 
FP is effective in the acute treatment of attacks of HAE-
1/2 is low. It also contains potential substrates for the 
generation of additional bradykinin and in theory could 
worsen attacks of angioedema. There may be a significant 
delay in getting FP and/or SDP in a timely manner—in 
some cases up to 24  h. Therefore, we felt strongly that 
frozen plasma products, although potentially beneficial, 
should only be used if other recommended therapies are 
not available, and that every effort should be made to 
ensure timely and appropriate therapy for HAE attacks 
[54, 55]. A decision to use FP will depend on local and 
patient factors and will require risk/benefit assessment 
of the respective merits of local FP treatment versus 
symptomatic relief only. Thus the threshold for treating 
when only FP is available would usually be limited to life-
threatening or severely painful attacks.
Clinical considerations
Early treatment leads to more rapid symptom resolution. 
Observational studies have suggested that early treatment 
can be efficacious in reducing the duration of an HAE 
attack in some patients [56–62]. Therefore, despite the 
absence of a high level of evidence, we strongly endorsed 
early treatment in an attempt to reduce morbidity and 
likely mortality. Interestingly, early treatment with 
C1-INH might also reduce the overall severity of an 
attack in addition to reducing the time to symptom 
relief [63]. Because of the potential barriers in accessing 
therapy in a timely manner, patients should be trained 
on how to self-administer therapies appropriate for the 
acute treatment of HAE attacks. If patients are not able to 
self-administer, efforts should be made to ensure that this 
therapy is made available to them without a significant 
delay (see Recommendation #36 for further details).
Clinical considerations
Attacks of HAE are unpredictable and potentially life 
threatening. Mortality due to laryngeal angioedema is 
well recognized [1]. All attacks of laryngeal angioedema 
should be considered medical emergencies, and therapies 
that have been shown to be effective in the treatment of 
HAE should be readily available and given immediately. 
It is also recommended that all patients with laryngeal 
edema, even following self-therapy, be assessed in the 
emergency department in the event that the angioedema 
does not respond to therapy and expertise in airway 
management is required [64].
Acute treatment and short-term prophylaxis of HAE 
in pregnant patients
Background
The gynaecologic and obstetrical management of patients 
with HAE-1/2 presents a unique challenge to healthcare 
providers. Pregnancy in particular may worsen, improve, 
or have no effect on angioedema attacks [65–68], and that 
effect may change from pregnancy to pregnancy [68]. At 
present there doesn’t appear to be a clear trend of whether 
symptoms are more severe in any specific trimester [67, 
69]. Vaginal delivery does not appear to be a trigger 
[65–68, 70] suggesting that women can forego STP for 
an anticipated uncomplicated vaginal delivery, although 
acute treatment should always be readily available. 
STP is recommended for C-sections or intra-partum 
instrumentation (see “Short-Term Prophylaxis” section for 
further details). Pregnant HAE patients should be closely 
monitored by an HAE expert in conjunction with a team 
of relevant medical professionals. Due to ethical reasons, 
there are no randomized controlled trial data assessing 
the efficacy and safety of medications used to treat attacks 
in pregnant HAE patients, although many cases have 
been documented. Guideline Authors recommended that 
healthcare professionals register the treatment of all their 
pregnant HAE patients in order to contribute to the body 
of literature on treatment outcomes in this group.
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The Committee affirmed that lactation and 
menstruation in patients with HAE were not specifically 
addressed in this guideline.
Clinical considerations
We unanimously agreed that the level of evidence for 
the use of pdC1-INH to treat acute HAE attacks in 
pregnancy was consensus, based on several case reports 
and observational studies [66–69, 71–74]. However, we 
strongly endorsed pdC1-INH as the treatment of choice 
in an effort to reduce morbidity and mortality in pregnant 
HAE-1/2 patients. For the same reason, despite specific 
evidence, we also strongly recommended using pdC1-
INH for angioedema attacks in pregnant HAE nC1-INH 
patients. The licensed indications and recommended 
dosing of pdC1-INH for the acute treatment of attacks 
are listed in Table  3. Icatibant [75] or rhC1-INH [76] 
may be used in the case of life-threatening attacks during 
pregnancy when pdC1-NH is not available or has not 
been efficacious for a particular patient.
Acute treatment of HAE in paediatric patients
Background
This section covers the acute treatment of paediatric 
patients (children ≤ 12  years of age and adolescents 
12–17  years of age), and will focus solely on HAE-1/2. 
While HAE can present at any age, the reported age of 
onset of attacks varies from 4.4 to 18 years with the mean 
age of first attack at 10 years [77]. Disease presentation in 
infancy is uncommon, but it is possible that abdominal 
symptoms of HAE are overlooked in infants. Abdominal 
discomfort and pain are common complaints in 
childhood and may easily be mistaken to have other 
causes in this population [78–82].
Clinical considerations
Symptom-free is in reference to those patients who have 
been diagnosed with inherited C1-inhibitor deficiency, 
but who have yet to demonstrate any symptoms of the 
disease. Due to the risks associated with the disease, all 
diagnosed patients should have ready access to acute 
treatment either on site or at a nearby medical facility. 
The following are drug-specific recommendations for the 
acute treatment of HAE attacks in paediatric patients.
Clinical considerations
When children are treated with pdC1-INH for HAE 
attacks, responses are consistent with that of adults 
[83]. Studies have demonstrated that the intervention is 
safe and well tolerated [31] in the paediatric population 
and effective in reducing time to symptom relief [32, 
84, 85]. Also similar to adults, data suggest that early 
treatment with pdC1-INH leads to more rapid symptom 
resolution [59, 62]. Dosing for pdC1-INH is 20 units (U)/
kg IV  Berinert® (CSL) [31, 83, 86, 87], 500 U IV  Cinryze® 
(Takeda) for children 10–25 kg, or 1000 U IV  Cinryze® 
for children > 25 kg [88–90].
Clinical considerations
Icatibant has been approved to treat patients ≥ 2 years of 
age in some countries (see Table  3) [91]. Depending on 
the age of the patient, the single SC dose of 0.4 mg/kg (to 
a maximum dose of 30  mg) injected into the abdomen 
can be self-administered, or given by a caregiver 
particularly in children. It does not require intravenous 
access, which can be challenging in paediatric patients 
[91–93].
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Clinical considerations
Intravenous rhC1-INH is a recombinant form of C1-INH 
that has been studied in adolescents and adults for the 
acute treatment of HAE attacks [37]. Dosing is weight 
based, 50 U/kg (unless a patient is ≥ 84 kg, then the dose 
is 4200 U), and delivered intravenously [94].
Clinical considerations
Ecallantide has been studied and approved for use in 
adolescents ≥ 12  year of age in the USA based on data 
from 4 clinical studies [49, 95]. This small pooled data set 
showed efficacy in children as young as 10 years of age. 
Ecallantide is administered as 3 SC injections for a total 
of 30 mg [49], but cannot be self-administered.
Diagnosis of HAE with normal C1-inhibitor
Background
The presence of HAE nC1-INH was first reported in 
Canada and Germany by Binkley and Bork respectively 
in 2000 [96, 97]. As of 2018, there were over 200 
identified families with the disease worldwide, however 
the true prevalence remains unknown and there is 
significant variation in prevalence between countries. 
HAE nC1-INH can be further subdivided by causative 
variant affecting coagulation factor XII (HAE-FXII), 
angiopoietin-1 (HAE-ANGPT), plasminogen (HAE-
PLG), and unknown (HAE-U) [11].
Clinical considerations
We recommended that the diagnosis of HAE nC1-INH 
be based on clinical evaluation by an expert physician. 
Criteria for the diagnosis of HAE nC1-INH include: 
(1) a history of recurrent angioedema in the absence of 
concomitant hives or use of medication known to cause 
angioedema; (2) documented normal or near normal 
C4, C1-INH antigen, and C1-INH function; and (3) 
either a genetic variant associated with the disease, or a 
family history of angioedema and documented lack of 
efficacy of chronic high-dose antihistamine therapy [16]. 
Healthcare providers should also have a strong index of 
suspicion for HAE nC1-INH if a patient presents with 
the above criteria and has failed corticosteroids and/or a 
trial of omalizumab. Testing for gene variants known to 
be associated with the condition should be performed 
where possible. The Guideline Authors affirmed that 
these diagnostic criteria are based on ideal feasibility 
and availability of the above tests and should not be 
considered absolute requirements in order to make the 
diagnosis of HAE nC1-INH.
Acute treatment of HAE with normal C1-inhibitor
Background
HAE nC1-INH is a rare disease that can be a challenge to 
diagnose with certainty as discussed above. This creates 
a unique set of challenges for patients since treatments 
are hard to access without a diagnosis. Patients may also 
be stigmatized due to a lack of understanding of their 
condition especially if they are presenting regularly to 
the emergency department with angioedema attacks, but 
have documented normal C1-INH. It has been suggested, 
without confirmatory evidence, that bradykinin may play 
a role in the pathogenesis, leading to speculation that 
therapies used for HAE-1/2 may be beneficial [98]. There 
is also indirect evidence that antihistamine therapy is not 
effective in this patient group [99].
Clinical considerations
Guideline Authors felt they could recommend trials of 
specific therapies that have proved effective in some 
cases because, while there have been neither significant 
case series nor controlled clinical trials studying 
therapeutic intervention for attacks in the HAE nC1-
INH population, these attacks are often severe and may 
be life-threatening. In addition to acute therapy, patients 
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should discontinue and avoid any known triggers such as 
estrogen-containing oral contraceptives or replacement 
therapy, DPP-IV inhibitors, neprilysin inhibitors, and 
ACE inhibitors [39–46].
Intravenous pdC1-INH has efficacy in reducing 
the duration and intensity of attacks of angioedema 
in patients with HAE nC1-INH (as shown by non-
controlled, retrospective studies on small case series 
recruited with non-predetermined homogeneous 
criteria) despite the fact that the pathogenesis of the 
angioedema, by definition, is not caused by a deficiency 
in C1-INH [15, 40, 41, 45].
With the same limitations as for pdC1-INH, there 
is evidence that blocking bradykinin-2 receptors with 
icatibant is an effective intervention for treating attacks 
in various body sites in the majority of HAE nC1-INH 
patients [15, 39, 100].
The Committee affirmed that these recommendations 
generalize to all HAE nC1-INH patients and are not 
subdivided by causative variant in this guideline.
Short-term prophylaxis
Background
Short-term prophylaxis (STP) refers to the practice of 
treating patients to reduce the risk of associated and 
consequent morbidity and mortality during a period of 
time when there may be an increased risk of having an 
angioedema attack.
It is well recognized that physical trauma, as can 
occur during medical and dental procedures, can induce 
episodes of angioedema [101–103]. Upper airway 
manipulation, including during dental surgery and 
intubation, is particularly high risk due to its association 
with upper airway swelling. However, even minor 
procedures can precipitate angioedema, and the ability 
to predict when this may occur cannot be made with 
certainty. Attacks can occur anywhere from hours to 
several days after a procedure [101]. Healthcare providers 
should educate their patients—regardless of whether 
they received STP—about the possibility of angioedema 
attacks happening within 72 hours post-procedure.
It is also thought that other causes, such as emotional 
stressors can precipitate attacks. Individual patients may 
also be aware of specific triggers that have been known 
to trigger their attacks. Despite these observations, there 
are no controlled clinical trials in this area, and data 
come from personal experience, retrospective reviews, 
and surveys [101, 102, 104, 105].
Clinical considerations
There was extensive discussion as to when STP should 
be used, and consideration was given to the development 
of a list of high- and low-risk procedures in this context. 
However, there is a lack of data regarding the specific 
risk associated with each of a wide range of medical, 
surgical and dental procedures, and that STP should 
be considered for some. One study assessed the risk of 
angioedema following surgery without pre-procedural 
prophylaxis as 5–30%, irrespective of type and extent of 
surgery [101]. Based on this, and our inability to link the 
risk of an attack to a specific procedure [101, 102], it was 
felt that STP should at least be considered for procedures 
that are near the upper airway, or cause trauma, or are 
known patient-specific triggers. This recommendation 
was intended to remain broad in its scope, as the risk 
of appropriate STP would likely be minimal compared 
to any real or perceived risk of not using STP when felt 
necessary. Ultimately, the decision of whether or not to 
use STP should involve both the patient and their HAE 
healthcare provider and may depend on several factors 
including the degree of physical trauma involved and 
whether or not the patient has had an attack previously 
under similar circumstances. Dental extraction, for 
example, is likely higher risk for inducing angioedema 
than dental cleaning or cavity restoration, and healthcare 
providers may choose to not use prophylaxis for perceived 
low-risk procedures unless similar procedures have 
precipitated attacks in the past. If the decision is made not 
to administer STP, all patients should have two doses of 
appropriate on-demand therapy immediately available as 
per Recommendation #23. Even those that receive STP 
should have two on-demand treatments available. What 
is not known from the current data is how many patients 
have been denied or have chosen not to pursue necessary 
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procedures due to perceived risks, or have not been 
offered STP. Ensuring access to STP may help mitigate 
the risk associated with procedures and enable patients to 
seek and receive the care they need [106].
Pre-procedural prophylaxis with pdC1-INH 
concentrate is recommended at a dose of 20  U/kg 
IV within an hour before a procedure. In one study, 
patients had about a 30% risk with no prophylaxis and 
a 15% risk with 500 U of pdC1-INH, which was reduced 
to about a 5% risk at 1000  U [102]. With 20  U/kg the 
average-sized person would be receiving 1500  U, which 
hopefully will reduce the 5% risk of an attack following 
a procedure. Furthermore, given that breakthrough 
attacks have occurred even with prophylactic pdC1-INH 
concentrates at 1000 U, at least two additional treatments 
for attacks should be available. In Europe,  Cinryze® is 
licensed in adults for 1000 U to be given within 24 h of 
an anticipated procedure or  Berinert® 1000 U within 6 h. 
The European paediatric licensing is dosed by weight 
with 500  U of  Cinryze® for children 10–25  kg (within 
24  h of an anticipated procedure) or 15–30  U/kg of 
 Berinert® (within 6 h) (see Table 3).
Attenuated androgens or frozen plasma may be 
considered for STP when pdC1-INH is not available and 
particularly if HAE-specific acute treatments are not 
available. When androgens are chosen for STP, danazol 
can be considered starting 5 days before the anticipated 
procedure or trigger, and continuing 2–3  days after 
the anticipated trigger (danazol 2.5 to 10  mg/kg/day, 
maximum 600 mg/day) [9]. Disadvantages with androgen 
therapy include perceived inferior efficacy to pdC1-INH 
concentrate. Attenuated androgens are not suitable in 
pregnancy or during breastfeeding, and a pregnancy test 
should be considered before initiation of therapy with 
androgens. Frequent short-term uses may be associated 
with similar effects seen with long-term androgen use 
as discussed in “Long-Term Prophylaxis of HAE-1 and 
HAE-2”. The optimal dose of frozen plasma for STP has 
not been determined but, based on cases in the literature, 
it is typically given as 2  U in adults and 10  mL/kg in 
children 1 to 2 h prior to a procedure [55, 107–109].
Anti-fibrinolytic agents such as tranexamic acid have 
been used for STP with suggested dosages of 25  mg/kg 
2–3 times daily to a maximum of 3–6 g per day, 5 days 
before and 2–5  days after a procedure or anticipated 
trigger. The efficacy for prevention of attacks, however, 
is unknown and this agent should be used only if other 
therapies are not available.
Lanadelumab (Takeda), a humanized monoclonal 
antibody against kallikrein, takes approximately 70  days 
to reach a steady state concentration [110], and is 
therefore not recommended for STP. Similarly, there is a 
delay in reaching the therapeutic steady state for a week 
or two with subcutaneous C1-INH suggesting it should 
not be used as STP. Data are lacking as to whether STP 
is necessary if patients are symptom free with either 
lanadelumab or subcutaneous C1-INH, and until these 
data are available STP, if indicated, should be used when 
prescribing either for LTP.
In general, pregnant HAE patients do not appear to 
require routine STP for uncomplicated vaginal deliveries 
[65, 67, 68, 70]. However, there are certain instances 
where STP could be considered prior to vaginal delivery 
including a history of severe HAE attacks, frequent 
attacks during the third trimester, or a history of genital 
edema secondary to mechanical trauma [66, 70, 111–
113]. STP is recommended in the case of a C-section 
or intra-partum instrumentation, and may need to be 
repeated, subject to drug half-life, if delivery hasn’t 
happened within a certain time period [66, 68]. As with 
other procedures, two doses of on-demand therapy 
should be available in case of an HAE attack.
Long-term prophylaxis in HAE-1 and HAE-2
Background
Long-term prophylaxis (LTP) refers to the use of ongoing, 
regular treatment to prevent attacks of HAE when 
on-demand treatment does not sufficiently meet patient 
treatment requirements as discussed below in “Approach 
to individualized therapy” section. Prophylactic therapy 
may be considered for patients with recurrent episodes 
of angioedema to reduce the frequency, duration and 
severity of attacks. The specifics of when to consider and 
when to initiate LTP are discussed below. 
Clinical considerations
The aim of LTP is to reduce the frequency and/or 
severity of attacks of HAE and minimize the impact of 
HAE on QoL, thereby enabling patients to live normal 
lives. Some patients may be candidates for long-term 
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therapy, and the benefits and risks associated with such 
treatments should be explored to optimize patient care. It 
is important to remember that no prophylactic regimen 
has been associated with the complete elimination of 
angioedema. Therefore, despite being on prophylaxis, all 
patients should be equipped to treat angioedema attacks 
in a manner consistent with Recommendation #3, and an 
acute treatment plan should be agreed to between patient 
and physician.
Clinical considerations
Controlled clinical trials have demonstrated that both 
IV and SC pdC1-INH used for prophylaxis in HAE-1/2 
reduces the number, duration, and severity of attacks of 
angioedema [36, 38, 114].
C1-inhibitor prophylaxis has traditionally been given 
intravenously [38]. More recent trials have shown 
higher levels of efficacy when C1-inhibitor is given as a 
higher dose subcutaneously. The subcutaneous route 
also reduces the inconvenience and medicalization 
associated with the intravenous route, and avoids hazards 
of repeated venipuncture and indwelling catheters 
[115], further improving QoL [116]. However, direct 
comparison between the IV and SC routes has not been 
subject to formal trial. 
Clinical considerations
Lanadelumab is a subcutaneously injectable, fully 
humanized, anti-active plasma kallikrein monoclonal 
antibody (IgG1/κ-light chain). It is administered as 300 mg 
every 2 weeks, however a dosing interval of 300 mg every 
4 weeks may be considered if a patient is well controlled 
(e.g., attack free) for more than 6 months [110]. 
Clinical considerations
Although there have not been any head-to-head 
comparisons of long-term prophylactic agents, hence 
a consensus level of evidence for efficacy, we strongly 
agreed that either subcutaneous pdC1-INH or 
lanadelumab are appropriate as first-line LTP.
Clinical considerations
Considerations when deciding to start prophylaxis are 
discussed below, in “Approach to individualized therapy” 
section. The decision to start LTP should be based on the 
efficacy of the therapy, its side effects and safety profile, 
and the patient’s preference. Although androgens and 
anti-fibrinolytics are not recommended as first line, these 
agents may be considered for LTP in those patients who 
have already obtained benefit from their use or who have 
difficulty obtaining first-line options. It should not be 
necessary for patients to fail other long-term prophylaxis 
therapies, such as androgens and anti-fibrinolytics, 
before using pdC1-INH or lanadelumab.
Controlled trials and observational studies have 
demonstrated that treatment with 17 α-alkylated anabolic 
androgens, such as danazol, reduces the frequency and 
severity of HAE attacks [117–122]. Although one of 
the trials was a randomized controlled trial, the level of 
evidence for the trial was not considered high as there 
were insufficient details on funding, sequence generation, 
and outcome reporting [120]. Historically, many patients 
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have been controlled with androgen therapy and their 
use in some patients may be acceptable provided that 
the lowest effective dose is used to achieve efficacy and 
minimize adverse events. Expert opinion suggests the 
optimal dose for danazol, to minimize adverse events, is 
≤ 200 mg/day [9, 98].
Androgens can affect serum lipid levels, can be 
hepatotoxic resulting in hepatitis, and have been 
associated with hepatocellular adenoma and, in very 
rare cases, carcinoma [118, 123, 124]. It is recommended 
that all patients on androgen therapy be monitored for 
hypertension and have a complete blood count, liver 
enzymes, urinalysis, serum α-fetoprotein, creatine 
phosphokinase and lipid profile performed every 
6 months, and an annual liver ultrasound [17].
Virilising effects of androgen therapy can occur and 
include menstrual irregularities, masculinization, 
irreversible voice alteration, and hirsutism. Psychological 
side effects include emotional irritability and lability, 
aggressive behaviour and depression. Androgens interact 
with several medications. They are contraindicated in 
pregnancy and lactation, before puberty, and in patients 
with androgen-dependent malignancy and hepatitis 
[123, 124]. Patients need to be made aware of these side 
effects when considering and while on androgen therapy, 
and physicians should carefully consider the risks and 
benefits for the particular patient.
There is a moderate level of evidence showing the 
benefit of the anti-fibrinolytic agent tranexamic acid 
as an LTP agent. This benefit was demonstrated in a 
randomized placebo-controlled trial with 18 subjects 
≥ 12 years taking 1 g of tranexamic acid three times a day 
[125], and a double-blind crossover study of ε-amino-
caproic acid in 9 patients aged 7 to 40  years [126]. 
These data suggested that anti-fibrinolytic agents could 
be useful for LTP for HAE-1/2. However, their role in 
current LTP was felt to be justified only in certain patient 
groups due to the lack of efficacy and the potential side 
effects at the dosage studied. The recommended dosage 
for tranexamic acid is 30–50 mg/kg daily divided in 2 or 3 
doses to a maximum of 6 g per day.
Clinical considerations
Since no LTP therapy completely eliminates the risk of 
attacks, all patients should have access to at least two 
doses of on-demand therapy and patient competency to 
administer such therapies should be routinely assessed. 
Effective treatment for attacks should also be sufficient 
to provide patients with enough time to access an urgent 
care centre.
Long-term prophylaxis in pregnant HAE patients
Background
When making decisions regarding LTP for pregnant 
patients, healthcare providers need to consider efficacy 
and safety of treatment for mother and infant throughout 
pregnancy, labour and delivery, as well as during the 
breastfeeding period. Given the rarity of HAE combined 
with the ethics of enrolling pregnant patients in clinical 
trials, it is unlikely there will be any placebo-controlled 
interventional studies assessing LTP treatment options 
prospectively in pregnant patients with HAE. The 
available evidence comes from observational studies, 
case reports, retrospective reviews, questionnaires, and 
expert opinion.
Clinical considerations
The data from observational studies [69, 127] and 
retrospective reviews [67, 68] demonstrated that pdC1-
INH was generally safe and not associated with any 
neonatal abnormalities or treatment-related adverse 
events during the study periods. Although the data were 
not of high quality, we strongly recommended pdC1-INH 
when LTP is required in pregnancy.
Clinical considerations
Androgens are contraindicated during pregnancy as 
these drugs can have significant effects on the normal 
development of the fetus, including masculinization. 
Potential effects on the female fetus include clitoral 
hypertrophy, labial fusion, urogenital sinus defect, 
vaginal atresia, and ambiguous genitalia [128–130].
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Long-term prophylaxis in paediatric HAE patients
Background
Long-term prophylaxis in the paediatric population 
needs to be flexible in order to accommodate changes 
in a patient’s hormones, stressors, and lifestyle [89]. 
Currently, there are limited data showing the use of 
newer, specific therapies for routine prophylaxis in 
children. 
Clinical considerations
The clinical studies assessing the use of prophylactic 
pdC1-INH in children have been of small sample size 
[84, 85, 131–134]. Pooled data from an RCT and its 
open-label extension study demonstrated that pdC1-
INH was effective and well tolerated for routine 
prophylaxis in children with HAE. Patients received 
IV infusions of pdC1-INH 1000  U (500  U for children 
ages 6 to 11) or placebo every 3 to 4  days. During the 
placebo-controlled pivotal trial, pdC1-INH reduced the 
number of angioedema attacks by nearly twofold (n = 4). 
During the open-label extension, pdC1-INH significantly 
decreased the pre-enrolment median monthly attack rate 
(n = 23). Adverse events during the studies were minimal 
(1 patient with pyrexia in the pivotal trial, and 1 patient 
with headache and nausea and another with infusion-site 
erythema considered related to pdC1-INH in the open-
label extension) [85]. Lanadelumab and SC pdC1-INH 
are indicated for routine prevention of recurrent attacks 
of HAE in patients aged 12 years and older (see Table 3).
Clinical considerations
Androgens are known to cause premature closure of the 
epiphyses [135, 136], among other significant side effects, 
and are therefore contraindicated as LTP in the paediatric 
population before Tanner stage 5. However due to their 
efficacy, as described above, and in the absence of other 
available options, androgens may be considered once 
patients have completed puberty. If androgen use is 
necessary, paediatric patients should start at the lowest 
effective dose. They should have regular monitoring for 
side effects.
Anti-fibrinolytics cannot be recommended for LTP 
in the paediatric population due to the lack of evidence. 
Where they have been studied in children, they have 
shown limited efficacy [133].
Similar to adults, paediatric patients should not be 
required to fail other non-specific therapies, such as 
androgens or anti-fibrinolytics, before proceeding to 
more specific LTP agents.
Long-term prophylaxis in HAE with normal C1-inhibitor
Background
Patients with HAE nC1-INH share similar clinical 
characteristics with HAE-1/2 patients, including the 
risk of random, unpredictable attacks of debilitating 
and potentially life-threatening angioedema [99]. These 
similarities have led to speculation that treatments used 
for LTP for HAE-1/2 may be beneficial for patients 
with HAE nC1-INH. However, due to the lack of data, 
a recommendation for this intervention could not be 
made. Guideline Authors felt strongly that more data are 
needed in this area and that appropriate trials should be 
done to help guide future treatment recommendations.
Clinical considerations
We did not reach consensus on the proposed 
recommendation for the use of progestins or tranexamic 
acid for LTP in patients with HAE nC1-INH. There is 
some evidence that progestins, anti-fibrinolytics and 
attenuated androgens may be efficacious in patients 
with HAE nC1-INH [45, 137]. Although some European 
countries have shown progestins to be effective, the 
same high doses used in Europe are not available in all 
countries [66]. Nevertheless, we wanted to re-iterate the 
importance of avoiding known triggers of angioedema 
such as estrogen-containing oral contraceptives or 
replacement therapy, DPP-IV inhibitors, neprilysin 
inhibitors, and ACE inhibitors [39–46].
Self-administration
Background
Self-administration refers to the treatment of patients 
outside of a healthcare facility either by the patients 
themselves or by a trained caregiver. The recognition and 
support of self-administration as treatment for HAE go 
back to the first international consensus document on 
HAE in 2003, and it has been repeatedly recommended 
in subsequent consensus statements and guidelines [9, 
17, 138]. It has been shown to be a safe and convenient 
option for patients, allows for early treatment, and 
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may reduce the overall treatment costs of this group 
when compared to hospital-based therapy [139, 140]. 
However, despite the demonstrated benefits of self-
administration and on-demand therapy in terms of 
efficacy and improved QoL, an online survey done in the 
USA revealed that only 8.1% of treating physicians had 
patients who self-treated and only 3.5% received home 
healthcare-assisted administration [141, 142]. Although 
specific data in Canada is lacking, there is little reason to 
believe it would differ significantly from these findings. 
Self-administration of blood products for rare blood 
disorders is not without precedent, and has been the 
cornerstone of effective therapy for haemophilia for more 
than three decades [143].
Treatment is more efficacious when attacks are treated 
early [144]. Evidence has shown that the earlier an attack 
is treated the sooner it resolves [35, 57, 145, 146]. The 
ability to treat an attack early depends on reducing the 
number of steps required between recognition of an 
attack that requires treatment and implementation 
of effective therapy. Obligating patients to travel to a 
healthcare facility to receive a therapy, which has been 
shown to be effective when administered at home or 
outside of a healthcare facility, adds to the delay in 
receiving treatment [2] and may result in many attacks 
not being treated. Patients may also face difficulties 
in accessing treatment if local healthcare facilities are 
unfamiliar with this condition. All therapies should be 
available to all HAE patients worldwide, and home- 
and self-administration are preferred because they 
reduce morbidity, absenteeism, cost, disease burden and 
potentially mortality, as well as improve QoL [17, 145, 
147].
Clinical considerations
Although the level of evidence was low for the 
recommendation that all patients should be trained 
on self-administration of HAE-specific therapies 
if they are suitable candidates, it was unanimously 
considered a strong recommendation. This is consistent 
with prior consensus statements and guidelines [18, 
19, 148]. The importance of early therapy should 
not be underestimated, and barriers that affect its 
implementation should be removed. Geographic 
and regional disparities in care are known to exist, 
and self-administration of therapy will remove these. 
Although, intravenous pd-C1INH requires special 
considerations including product tracking and patient 
training, the use of blood products for self-administration 
is not unique. Haemophilia self-administration programs, 
which are similar, have been implemented and have been 
shown to be effective [143, 149]. Another example is self-
administration of subcutaneous immunoglobulin for 
patients with primary immunodeficiency disease [150, 
151]. Recent licensing of subcutaneously administered 
therapies will further simplify self-administration [114, 
152, 153].
Although not all patients will be suitable candidates 
for self-administered therapy, the option should be 
considered in the overall care plan for HAE patients. 
If patients are considered appropriate and willing to 
learn self-administered therapy, they should agree to 
specific criteria as outlined in previously published 
international home-therapy guidelines [154, 155]. 
With self-administered therapy, patients need to be 
regularly monitored to ensure appropriate control of 
their symptoms, compliance, and competency. This is 
discussed further in “Approach to individualized therapy” 
section below.
Approach to individualized therapy
Background
HAE is a dynamic chronic disease, and attacks of 
angioedema can vary in frequency and severity over the 
patient’s lifetime. This variability makes it important for 
patients to be evaluated regularly to ensure that therapy 
is appropriate, used correctly, and that side effects of 
therapies are being minimized. A recently published 
document outlines an approach to monitoring attack 
frequency and severity [148].
Perhaps one of the most challenging areas in patient 
treatment is deciding when to start or stop LTP therapy. 
Although guidelines exist on which agents to use when 
starting LTP, there is no evidence comparing the use of 
LTP to acute on-demand therapy regarding benefit and 
risk. In the absence of such evidence, given the clinical 
importance of this therapeutic approach, the Committee 
attempted to determine which variables should be 
considered when trying to decide when to start or stop 
LTP.
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Clinical considerations
There was considerable discussion regarding factors that 
should be considered when deciding to start LTP. It was 
generally agreed that key considerations in making the 
decision included the efficacy of on-demand therapy to 
control the severity and frequency of attacks. Although in 
the past some consensus documents have tried to define 
the number and severity of attacks as a reference point 
to consider when to start LTP [10], there was significant 
concern about the arbitrary nature by which this would 
be defined. This approach might lead to denying LTP 
to patients whose QoL is impacted despite not meeting 
specific predefined criteria. It was felt that although the 
frequency of attacks is important, it is only one among 
many factors that should be considered, along with: 
severity of previous attacks, how readily patients can 
access emergency treatment, their ability to administer 
on-demand therapy, and impact on QoL.
Although the aim of LTP is to reduce the number 
and severity of attacks, it does not completely eliminate 
the risk. Patients must be aware that starting LTP does 
not mean that they will no longer have attacks and that 
attacks which occur can still be fatal. All patients must 
have a plan to treat attacks on demand despite being on 
LTP therapy. All patients must be monitored to ensure 
that LTP is efficacious and that side effects are being 
recorded [148].
When starting LTP it is important to understand and 
emphasize that LTP is not necessarily a lifelong therapy 
and that treatment needs ongoing re-evaluation. It may 
be helpful to try to objectively define patient expectations 
when starting LTP. Part of the monitoring process should 
be to examine these goals and ensure they are being met.
The decision to stop LTP also generated significant 
discussion. All Conference Participants felt LTP with 
androgens should be stopped immediately if a patient 
became pregnant or was breastfeeding. Reducing or 
stopping LTP could be considered if the patient has 
been stable with no evidence of breakthrough attacks of 
angioedema for a protracted period of time, though no 
specific guidance can be provided on a specific duration 
of symptom control and the decision must involve the 
patient. If the decision to reduce or stop LTP is made, 
all patients must ensure that they have ongoing access 
to the administration of appropriate on-demand therapy 
for attacks as is consistent with Recommendation #36. 
All members of the patient’s comprehensive care team 
should be aware of the plan to reduce or stop LTP in case 
complications arise.
When stopping LTP with attenuated androgens or anti-
fibrinolytics, the majority of Conference Participants 
agreed that a gradual taper is recommended, if the patient 
is not pregnant, while monitoring the frequency of and 
the impact on the patient’s QoL. When stopping LTP 
with pdC1-INH or lanadelumab it was felt it could either 
be stopped abruptly or the frequency of administration 
decreased, while monitoring the patient’s response.
The Committee unanimously agreed that the decision 
to start or stop LTP should be made jointly by the 
patient and an HAE specialist. The patient needs to 
be informed of the risks and benefits of all therapies, 
as discussed in the relevant sections above, to enable 
making an informed decision. Additionally, long-term 
effects on vein health need to be taken into account when 
considering repeated IV infusions.
Quality of life
Background
The Constitution of the World Health Organization 
(WHO) defines health as, “A state of complete physical, 
mental, and social well-being not merely the absence of 
disease”. It follows that the measurement of health and 
the effects of healthcare must include not only changes 
in the frequency and severity of diseases, but also an 
estimation of well-being and disease-specific health-
related quality of life (HRQoL). The impact of HAE on 
a person’s HRQoL can be considerable. A survey done 
in the USA in 2004 revealed that 85% of patients were 
afraid of sudden closure of their airway, 75% experienced 
intolerable pain, and 53% were concerned about 
transmitting HAE to their offspring [156]. Another study 
of 457 HAE patients from the USA reported significantly 
poorer HRQoL versus population norms. [157]. 
Productivity was also markedly impaired, including 
34% overall work impairment. Because of their most 
recent HAE attack, workers lost a mean of 3.3 days and 
students lost a mean of 1.9  days. A Swedish registry of 
HAE patients documented missed days from work and 
school [158]. A multicentre European Study recorded 
absenteeism from work and school as well as marked 
loss in productivity with the most recent attack and in 
between attacks [159].
The Burden of Illness Study in Europe (Denmark, 
Germany, Spain) showed that HAE had a high impact on 
daily activities during attacks and also impacted patients’ 
daily activities between attacks [159–161]. Patients 
reported substantial anxiety about future attacks, 
traveling, and passing HAE to their children [161]. Attack 
severity was shown to be related to absenteeism [158, 
159], and 51% (n = 84) of patients indicated that HAE had 
hindered their career/educational advancement [159].
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European studies employing general HRQoL instruments 
also showed that attacks had a negative effect on HRQoL 
[162] including, specifically, attack frequency, as measured 
by the European Quality of Life 5 Dimensions Questionnaire 
(EQ-5D) [158] or the Short Form 36 Health Survey (SF-36) 
[163]. Prophylactic therapies, including lanadelumab and 
both IV and SC pdC1-INH, all demonstrated improvements 
in HRQoL [38, 114, 147, 152, 164].
An international specific HRQoL questionnaire for 
adult patients with HAE-1/2 has been developed called 
the HAE-QoL [165, 166]. During the development of the 
HAE-QoL, the factors cited most often by both experts 
and patients as affecting their QoL included potentially 
life-threatening attacks; the adverse side effects of 
medication (in several cases associated with chronic 
treatment); the unavailability of specific acute treatment 
at several healthcare centres; hereditary transmission; 
the lack of a known trigger which could be avoided; and 
the fact that it is a rare disease about which healthcare 
professionals know very little [165]. 
Clinical considerations
Assessment of HAE control as it relates to the frequency, 
duration and severity of attacks is not the only thing to 
consider when monitoring patients. Data suggests that 
factors which relate to a patient’s QoL are important 
when following patients with HAE. Although the HAE-
QoL was developed specifically for adult HAE-1/2 
patients, it has not been shown to be responsive when 
a 6-month recall period was used in one small study 
[167]. The Angioedema Quality of Life Questionnaire 
(AE-QoL) [168, 169] has been used in a large clinical 
trial, and although it was found to be responsive [152], 
it may not be specific enough to assess all the problems 
faced by patients with HAE. Validated instruments that 
are short, specific and responsive are needed to routinely 
assess HAE patients and optimize their management.
Comprehensive care
Background
Comprehensive care of patients is based on integration 
of the organization, delivery, and management of services 
related to diagnosis, treatment, care, rehabilitation 
and health promotion. Many rare disease groups have 
adopted the comprehensive care model, and there is 
evidence in other rare diseases that this model results 
in better patient outcomes and reduced costs [143]. 
Haemophilia has used this model for decades. HAE 
is similar to other rare blood disorders, including 
haemophilia, because it is a chronic condition that 
is potentially life threatening and requires a highly 
specialized, multidisciplinary team to manage. However, 
although HAE is similar to other conditions, it is also 
different enough to require its own framework to meet 
the specific needs of these patients. The recommendation 
to provide comprehensive care for patients with HAE is 
not new and exists in previously published guidelines. 
The specific elements of comprehensive care for HAE 
were published previously and are listed in Table 4.
Table 4 Requirements for comprehensive care in the management of hereditary angioedema patients [9]
Best Clinical Treatment outcomes including
 a. A comprehensive care team made up of nurse coordinator, clinician, social worker, data manager, pain management specialist, genetic counsellor, and administrative 
support
 b. Access to specialized diagnostic testing
 c. Access to home treatment
 d. A networked Patient Information System to facilitate product recalls—collect data on therapy outcome measures and safety, and facilitate participation in clinical trials
 e. Access to clinical advances as they become available
 f. Access to 24 hour support
 g. Access to up‑to‑date standards of care, including standardized wallet cards
 h. Tracking and intermittent audit of quality outcomes including beneficial and adverse outcomes through secure, comprehensive and networked data management
Education of patients and staff regarding
 a. Responsible Self/Family Care (home care model) with home and self‑infusion/administration instruction and support
 b. Developments in the cause, diagnosis, treatment, outcomes, and prognosis of HAE
 c. Changes in the administrative management of the clinic
An environment conducive to research including
 a. Access to and support for clinical trials of new treatments
 b. Access to and support for translational research in diagnosis and prognosis
 c. Access to and support for psychosocial research such as quality of life studies
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Clinical considerations
Although the importance of the comprehensive care 
model in HAE was affirmed unanimously by Guideline 
Authors, and specific recommendations have existed 
with respect to its requirements, this care model is not 
available to all patients with HAE and every organization 
may adapt this model to its own context. Despite this, 
the fundamentals of comprehensive care should strive 
to be uniform and equally accessible within and between 
countries. Treatments for HAE can be expensive; however 
inappropriate treatment of HAE may be even more costly. 
Guideline Authors affirmed that ongoing monitoring of 
comprehensive care programs is essential to measure 
their efficacy as well as their impact on patients’ outcomes 
such as disease control, morbidity and mortality, hospital 
admissions, QoL, and economic effects. 
Clinical considerations
Patient organizations play a key role in supporting HAE 
patients and their caregivers. These organizations advocate 
for access to management and treatment for HAE patients, 
not only to control their disease, but to support them in 
fulfilling their potential at home, school, work, and in their 
relationships. All patients should be encouraged to join 
their local and international patient organizations.
Registries
Background
Patient registries are a proven method for tracking 
clinical outcomes. Haemophilia, for example, has had 
vein-to-vein blood tracking since the early 1980s. 
Australian and Canadian bleeding disorder registries 
already exist for tracking the movement of blood 
products and provide a means for informing patients 
if any products they received have been recalled. As 
per the European Organisation for Rare Diseases 
(EURORDIS), the National Organization for Rare 
Disorders (NORD) and the Canadian Organization for 
Rare Disorders (CORD), rare disease patient registries 
should be recognized as a global priority in the field of 
rare diseases. Key principles of their joint declaration for 
rare disease registries include that registries should be 
centred on a disease group or group of diseases rather 
than a therapeutic intervention, they should encompass 
the widest geographic scope possible, and they should 
include data directly reported by patients as well as 
healthcare professionals [170]. A patient- and physician-
driven global disease registry for HAE started in 2018 
and is now recruiting [171].
Clinical considerations
Patients enrolled in an HAE registry will have a traceable 
timeline of their treatment with blood products as well as 
a way to report adverse events through the registry. An 
HAE registry, especially a global one, will also provide a 
growing repository of data for research in the field with 
the aim to improve patient care.
Conclusions
This update to the 2014 Canadian Hereditary 
Angioedema Guideline is the collaborative effort of 
Canadian and international hereditary angioedema 
(HAE) experts and patient groups led by the Canadian 
Hereditary Angioedema Network. It aims to optimize 
the management of patients with HAE worldwide by 
providing current, evidence-based recommendations to 
healthcare providers who are either managing patients 
with HAE or who are likely to encounter them in their 
practice.
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IgG1: immunoglobulin G1; IV: intravenous; LTP: long‑term prophylaxis; 
NORD: National Organization for Rare Disorders; pdC1‑INH: plasma‑derived 
complement component 1 inhibitor; QoL: quality of life; RCAH: Réseau 
Canadien d’angioédème héréditaire; RCT : randomized controlled trial; 
rhC1‑INH: recombinant human complement component 1 inhibitor; SC: 
subcutaneous; SDP: solvent detergent plasma; SF‑36: Short Form 36 Health 
Survey; STP: short‑term prophylaxis; U: international units; VAS: Visual Analog 
Scale; WHO: World Health Organization.
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Appendices
Appendix 1: Search strategy
Database: Ovid MEDLINE
Search conducted on June 27, 2018 and November 4, 
2018 by Kelly Lang-Robertson, MLIS
Results previously identified in the October 2013 
search conducted to support the 2014 guideline were 
manually removed from the new set of results.
Inclusion criteria
• English language publications
• Human subjects
• ≥ 5 subjects in each comparison group
• Original results published in an indexed journal (i.e., 
no data from abstracts/posters included)
• Population: Patients diagnosed with type I or 
type II hereditary angioedema or hereditary 
angioedema with normal C1-INH of any age, 
including pregnant and pediatric populations
• Intervention—addressed at least one of: 
• Acute treatment
• C1-INH, rhC1-INH (ruconest), kallikrein 
inhibitors (ecallantide), bradykinin receptor 
antagonists (icatibant), antifibrinolytic 
drugs (tranexamic acid), solvent/detergent-
treated plasma (SDP), fresh frozen plasma 
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(FFP), frozen plasma (FP), epinephrine, 
corticosteroids, H1 antagonists, H2 
antagonists
• Long-term prophylaxis 
• C1-INH (IV or subcutaneous), attenuated 
androgens (danazol), antifibrinolytics 
(tranexamic acid), rhC1-INH (ruconest), 
synthetic steroids (tibolone), e-aminocaproic 
acid (EACA), oral kallikrein inhibitors 
(BCX7353, avoralstat), plasma kallikrein 
inhibitors (lanadelumab), anti-Factor XIIa 
antagonist monoclonal antibody (CSL-312)
• Short-term prophylaxis 
• C1-INH (IV or subcutaneous), attenuated 
androgens (danazol), antifibrinolytics 
(tranexamic acid), anabolic steroids, fresh 
frozen plasma (FFP), frozen plasma (FP)
• Comparison: 
• Any, including placebo, regular treatment, or no 
intervention
• Outcome: 
• Frequency or severity of attacks, or symptom 
relief including at least one of:
• Time to symptom relief (onset or complete 
resolution)
• Mean symptom complex severity score 
(MSCS score)
• Treatment outcome score (TOS)
• Attack duration
• Time to treatment
• Rebound/relapse
• Number of attacks (e.g., median per year or 
per month)
• Health related quality of life
• Work productivity activity index
• Depression scores
• Anxiety scores
Note: Intermediate outcomes such as laboratory 
measures are not included (e.g., mean serum 
concentrations of functional C1-INH).
Appendix 2: Levels of evidence and strength 
of recommendation
Note: Levels of evidence (Table  5) and strength of 
recommendation (Table  6) were adapted from GRADE 
[20–22]. GRADE is considered ‘‘outcome centric,’’ 
and traditionally recommends a single rating for each 
outcome across the full body of evidence.
Table 5 Levels of evidence
If no published evidence was identified in an area, but Guideline Authors determined that it was important to make a recommendation, this was labeled as Consensus
Quality level Definition
High We are very confident that the true effect lies close to that of the estimate of the effect
Moderate We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different
Low Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very Low We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
Table 6 Strength of recommendation
Recommendations can be either STRONG or WEAK
 Strength of recommendation is determined by
  1. Quality of evidence
   The higher the quality of evidence, the higher the likelihood that a Strong recommendation is warranted
  2. Balance between desirable and undesirable effects
   The larger the difference between the desirable and undesirable effects, the higher the likelihood that a Strong recommendation is warranted
  3. Values and Preferences
   The more values and preferences vary, or the greater the uncertainty in values and preferences, the higher the likelihood that a Weak recommendation is warranted
  4. Costs (resource allocation)
   The higher the costs of an intervention—that is, the greater the resources consumed—the lower the likelihood that a Strong recommendation is warranted
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Determining levels of evidence
All non-randomized, non-blinded trials were considered 
to be Low level evidence.
All randomized controlled trials were considered to be 
High level evidence, and were downgraded based on the 
following parameters:
Parameters Examples 
of limitations
Effect on level 
of  evidencea
Limitations of 
design/risk of bias 
(Cochrane Risk of 
Bias tool)
Lack of allocation 
concealment
Lack of adequate 
sequence 
generation
Lack of blinding
Incomplete data
Selective reporting
Other limitations 
such as stopping 
early
Majority of items 
not satisfied or not 
reported = downgraded 
by 1 level
Inconsistency Large variation in 
effect
Poor heterogeneity 
of results
Downgraded by 1 level
Imprecision of 
results
Small sample size
Wide confidence 
intervals around 
the estimate of the 
effect
Study is 
underpowered
Noted but not 
downgraded
Publication bias Bias introduced 
due to significant 
industry funding
Noted but not 
downgraded (majority 
of studies were industry 
funded)
Indirectness/
generalizability
Study population 
or setting differs 
significantly from 
population of 
interest
Not applicable
a
 If it was determined that the limitation was significant, the Level 
of Evidence was downgraded by 2 levels
Factors considered when deciding on a Strong or Weak 
recommendation
• Uncertainty in the estimates of likely benefit, and 
likely risk, inconvenience, and costs
• Importance of the outcome that treatment prevents
• Magnitude of treatment effect
• Precision of estimate of treatment effect
• Risks associated with therapy
• Burdens of therapy
• Risk of target event
• Costs
• Varying values
The implications of a Strong recommendation are
• Clinicians: Most patients should receive the 
recommended course of action
• Patients: Most people would want the recommended 
course of action and only a small proportion would 
not
• Policy makers: The recommendation can be adopted 
as a policy in most situations
The implications of a Weak recommendation are
• Clinicians: Different choices will be appropriate for 
different patients, and you must help each patient to 
arrive at a management decision consistent with her 
or his values and preferences
• Patients: Most would want the recommended course 
of action, but many would not
• Policy makers: Policy making will require substantial 
debate and the involvement of many stakeholders
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